Myriad Genetics MYGN Net proceeds from sales of subsidiary shares
Net proceeds from sales of subsidiary shares at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.
The official record: Myriad Genetics’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Myriad Genetics's net proceeds from sales of subsidiary shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Myriad Genetics's net proceeds from sales of subsidiary shares?
- Myriad Genetics (MYGN) reported net proceeds from sales of subsidiary shares of $0 in Q4 2025.
- What does net proceeds from sales of subsidiary shares mean?
- Represents the net cash inflow generated from the sale of equity shares to the public during an initial public offering or subsequent equity financing rounds. This metric is a primary indicator of the company's ability to raise external capital to fund growth, research, or debt repayment. It reflects investor confidence and the company's access to capital markets.